Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT05616195
Starting soon Observational

Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors

NCT05616195 · tracked via the Priya Life Science China tracker
Sponsor
Henan Cancer Hospital
Phase
Observational
Started
2024-12-28
Last updated
2024-01-18

Condition(s) studied

Malignant Tumor

Investigational drug(s) / intervention(s)

3D printed bone prosthesis replacement surgery

3D printed bone prosthesis replacement surgery: To report the postoperative complications and limb function of patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital.

Study summary

To report the patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital in the next 10 years, and collect the postoperative complications and limb function of these patients.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: Men and women of all ages are welcome. Pathologically confirmed in our hospital as a subtype of malignant tumor. He received 3D printed bone prosthesis replacement in our hospital. Exclusion Criteria: Not applicable.

Primary outcome measure(s)

  • complications — From surgery to 24 months after surgery
    Complications were collected from patients who underwent 3D-printed bone prosthesis replacement surgery.
  • Limb function — Patients were enrolled until 24 months after surgery
    Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.

Trial sites (1)

FacilityCityRegionStatus
Department of Bone and Soft Tissue ,Henan Cancer Hospital Zhengzhou Henan

More Henan Cancer Hospital trials in China

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer Recruiting
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG Recruiting
Application of Antiosteoporosis Therapy in Osteolysis Starting soon
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial Recruiting
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) Recruiting

Other trials for the same condition

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2 Recruiting
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors Active, not recruiting
Study on the Efficacy and Safety of Different Doses of PEG-rhG-CSF for Primary Prevention of Febrile Neutropenia Enrolling by invitation
Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life Recruiting
Application of LARS Ligament in Bone Prosthesis Replacement Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05616195 on ClinicalTrials.gov ↗ ← All trials in China